Neal et al. (2017) carried out a three-arm, randomized phase II clinical trial to determine the efficacy of erlotinib (150 mg/day), cabozantinib (60 mg/day), and erlotinib (150 mg/day) plus cabozantinib (40 mg/day) as second- or third-line treatment for patients with non-squamous EGFR wild-type NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.